TCR2 Therapeutics
675 West Kendall Street
Suite I
Cambridge
Massachusetts
02142
United States
Tel: 617-475-8469
Website: http://www.tcr2.com/
Email: info@tcr2.com
About TCR2 Therapeutics
At TCR2 Therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. We have developed a unique proprietary TRuC™ platform based on T cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete T cell receptor (TCR). Our TRuC™ variants can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. We have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe TRuC™-T cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic.The company was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. We have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Dr. Patrick Baeuerle
CEO: Garry Menzel, PhD and MBA
CSO: Robert Hofmeister, PhD
Acting CSO: John Pallies
Chief IP Counsel: Gregory Sieczkiewicz, PhD and JD
Head of Corporate Development: Helen Ho, PhD
Manager of Human Reources & Office Dynamics: Eva Quinn
TECHNOLOGY:
Please click here for TCR2 Therapeutics's technology.
116 articles about TCR2 Therapeutics
-
TCR² Therapeutics to Present at the Needham Healthcare Conference
4/8/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will present an update on Company progress at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021 at 8:00am E.T. using a virtual platform.
-
TCR2 Therapeutics Leases Manufacturing Space in Maryland, Autolus Backs Out of U.S. Expansion
3/30/2021
After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville. -
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
3/29/2021
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturing Practice (cGMP) build-out
-
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3/11/2021
- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 - Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 - Raised gross proceeds of $140M in a follow-on offering in January; extended cash runway into 2024
-
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
3/10/2021
TCR2 Therapeutics Inc. announced that three e-poster presentations featuring new clinical data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for treatment refractory mesothelin-expressing solid tumors and preclinical data on its pipeline programs will be presented at the American Association for Cancer Research Virtual Annual Meeting, taking place April 10-15, 2021.
-
TCR² Therapeutics to Participate in Two Upcoming Conferences in March
3/3/2021
TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at two upcoming conferences in March using a virtual platform. Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, will present corporate presentation at the H.C. Wainwright Global Life Sciences Conference
-
TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference
2/17/2021
TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, and Alfonso Quintás-Cardama, M.D., Chief Medical Officer of TCR 2 Therapeutics, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 20
-
TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors
2/4/2021
TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Shawn Tomasello to its Board of Directors.
-
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
1/20/2021
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share.
-
Last year was a record number of IPOs in the biotech industry, with 81 raising $13.5 billion. With this kind of a start, 2021 may be scorching.
-
TCR² Therapeutics Announces Proposed Public Offering of Common Stock - Jan 19, 2021
1/19/2021
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock.
-
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
1/8/2021
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 - Initial data from ongoing TC-110 Phase 1/2 trial anticipated in 2021 - IND for third program on track to file in 2021 - Preclinical data from allogeneic TRuC-T cell program targeting mesothelin anticipated in 2021 - Preclinical data presentations from new autologous TRuC-T cell programs anticipated in 2021
-
TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference
12/21/2020
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress at the 39th Annual J.P. Morgan Healthcare Conference
-
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors
12/13/2020
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.
-
TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
11/12/2020
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.
-
TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity
11/10/2020
TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company has established a manufacturing partnership with ElevateBio, LLC, to leverage the extensive technical capabilities at ElevateBio BaseCamp, a world-class cell and gen
-
TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
9/29/2020
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Monday, October 5, 2020
-
TCR2 Therapeutics to Participate in Two Upcoming Conferences in September
9/8/2020
TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, will present an update on Company progress at two upcoming conferences in September using a virtual platform. H.C. Wainwright 22 nd Annual Global Investment Conference on September 14, 2020 at 12:30pm
-
TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/12/2020
TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%
-
TCR² Therapeutics Announces Pricing of Public Offering of Common Stock
7/28/2020
TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $15.50 per share.